Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M)
Form 8-K Product Sales Detail & Form 10-Q / 10-K Other Product Sales Footnote
Latest, FY2025
719
Period ended Dec 31, 2025
Change on a year earlier
-5.1%
758 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 719 | -5.1% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 758 | +362.2% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 164 | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Breakdown
What makes up ultra-rare products (ravicti, procysbi, actimmune, buphenyl & quinsair) — worldwide product sales ($m)
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M)685 · FY2025
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Rest of World (ROW) product sales ($M)34 · FY2025
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide reported sales growth YoY (%)-5.0% · FY2025
- RAVICTI (glycerol phenylbutyrate — Urea Cycle Disorders) — U.S. sales ($M)337 · FY2025
- PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M)233 · FY2025
Cite this data
StockData. (2026). Amgen Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_ultra_rare_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.